Daily Stock Analysis, ABUS, Arbutus Biopharma Corp, priceseries

Arbutus Biopharma Corp. Daily Stock Analysis
Stock Information
Open
5.85
Close
5.75
High
5.90
Low
5.70
Previous Close
5.85
Daily Price Gain
-0.10
YTD High
8.25
YTD High Date
Oct 3, 2017
YTD Low
2.35
YTD Low Date
Jan 24, 2017
YTD Price Change
3.25
YTD Gain
130.00%
52 Week High
8.25
52 Week High Date
Oct 3, 2017
52 Week Low
2.35
52 Week Low Date
Jan 24, 2017
52 Week Price Change
3.05
52 Week Gain
112.96%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 22. 2017
3.70
Sep 12. 2017
4.29
14 Trading Days
16.04%
Link
LONG
Sep 13. 2017
4.50
Oct 2. 2017
5.97
13 Trading Days
32.63%
Link
Company Information
Stock Symbol
ABUS
Exchange
NasdaqGS
Company URL
http://www.arbutusbio.com
Company Phone
-
CEO
Mark J. Murray
Headquarters
-
Business Address
-
Sector
Healthcare
Industry Category
Drugs
Industry Group
Biotechnology
CIK
-
About

Arbutus Biopharma Corp. is a biopharmaceutical company. It focuses on on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection, a disease of the liver caused by the hepatitis B virus. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.

Description

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.